Literature DB >> 24030206

Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown.

Matthew R Halliday1, Nunzio Pomara, Abhay P Sagare, Wendy J Mack, Blas Frangione, Berislav V Zlokovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24030206      PMCID： PMC4047029          DOI： 10.1001/jamaneurol.2013.3841

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  9 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

Authors:  Robert D Bell; Ethan A Winkler; Itender Singh; Abhay P Sagare; Rashid Deane; Zhenhua Wu; David M Holtzman; Christer Betsholtz; Annika Armulik; Jan Sallstrom; Bradford C Berk; Berislav V Zlokovic
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

3.  Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.

Authors:  B D Zipser; C E Johanson; L Gonzalez; T M Berzin; R Tavares; C M Hulette; M P Vitek; V Hovanesian; E G Stopa
Journal:  Neurobiol Aging       Date:  2006-06-16       Impact factor: 4.673

4.  The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients.

Authors:  Karin Hultman; Sidney Strickland; Erin H Norris
Journal:  J Cereb Blood Flow Metab       Date:  2013-05-08       Impact factor: 6.200

Review 5.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

6.  Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder.

Authors:  Nunzio Pomara; Davide Bruno; Antero S Sarreal; Raymundo T Hernando; Jay Nierenberg; Eva Petkova; John J Sidtis; Thomas M Wisniewski; Pankaj D Mehta; Domenico Pratico; Henrik Zetterberg; Kaj Blennow
Journal:  Am J Psychiatry       Date:  2012-05       Impact factor: 18.112

7.  Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Authors:  K Blennow; A Wallin; P Fredman; I Karlsson; C G Gottfries; L Svennerholm
Journal:  Acta Neurol Scand       Date:  1990-04       Impact factor: 3.209

Review 8.  Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease.

Authors:  Berislav V Zlokovic
Journal:  JAMA Neurol       Date:  2013-04       Impact factor: 18.302

Review 9.  Fibrinogen and altered hemostasis in Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Daria Zamolodchikov; Hyung Jin Ahn; Sidney Strickland; Erin H Norris
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472
  9 in total
  59 in total

Review 1.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

2.  Apolipoprotein E Regulates Injury-Induced Activation of Hippocampal Neural Stem and Progenitor Cells.

Authors:  Sue Hong; Patricia M Washington; Ahleum Kim; Cui-Ping Yang; Tzong-Shiue Yu; Steven G Kernie
Journal:  J Neurotrauma       Date:  2015-06-11       Impact factor: 5.269

Review 3.  Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications.

Authors:  Johann Steiner; Kolja Schiltz; Hans-Gert Bernstein; Bernhard Bogerts
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

4.  High HbA1c level is correlated with blood-brain barrier disruption in syphilis patients.

Authors:  Feng Wang; Hua Ge; Xinhui Su; Ru Wang; Jianqi Zeng; Jiayin Miao
Journal:  Neurol Sci       Date:  2019-08-22       Impact factor: 3.307

Review 5.  Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps.

Authors:  Liying Corinne Lee; Michele Q L Goh; Edward H Koo
Journal:  Bioessays       Date:  2017-07-21       Impact factor: 4.345

6.  Antibody pharmacokinetics in rat brain determined using microdialysis.

Authors:  Hsueh-Yuan Chang; Kasey Morrow; Emily Bonacquisti; WanYing Zhang; Dhaval K Shah
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

Review 7.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 8.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 9.  Establishment and Dysfunction of the Blood-Brain Barrier.

Authors:  Zhen Zhao; Amy R Nelson; Christer Betsholtz; Berislav V Zlokovic
Journal:  Cell       Date:  2015-11-19       Impact factor: 41.582

10.  Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.

Authors:  Matthew R Halliday; Sanket V Rege; Qingyi Ma; Zhen Zhao; Carol A Miller; Ethan A Winkler; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.